Expanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development Rights

NEXT STORY
resTORbio Announces Initiation of Phase 1b/2a Trial of RTB101 in Parkinson’s Disease
PREV STORY
Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

American Health Council Names Sarah Forsythe, MS, RN, BSN to Nursing Board

NEW YORK, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Sarah Forsythe, Clinical Quality Specialist at ...

author_avatar
NASDAQ Market News

INNATE PHARMA : Preliminary activity observed of the combination of monalizumab and durvalumab in patients with colorectal cancer

preliminary DATA from a phase I dose escalation and expansion study of monalizumab and ...

author_avatar
NASDAQ Market News

Cellectar Biosciences to Present at the 5th Annual SeeThru Equity Microcap Investor Conference

MADISON, Wis., May 24, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused ...

author_avatar
NASDAQ Market News